Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
21 June 2017
E-002920/2017
Answer given by Mr Andriukaitis on behalf of the Commission

In accordance with Article 168(7) of the Treaty on the Functioning of the European Union Member States are responsible for the organisation and delivery of health services and medical care, including prescriptions for medicinal products(1).

The Commission supports Member States through the governmental expert group on mental health and well-being as a forum to exchange information and best practices on mental health, where issues such as the use of medicinal products could be discussed.

There are no activities under way or planned to monitor specific treatment for children or teenagers.

More generally, the Commission supports Member States in their efforts to review their mental health policies and share experiences in improving policy efficiency and effectiveness on the basis of the European Framework for Action on Mental Health and Wellbeing(2).

In addition, the EU-Compass for Action on Mental Health and Well-being(3) provides a forum to report progress and exchange good practices in areas such as prevention of depression and suicide, mental health at work and in schools, e-health and access to mental healthcare.

(1)http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:12012E/TXT&from=EN
(2)http://www.mentalhealthandwellbeing.eu/publications
(3)http://ec.europa.eu/health/mental_health/eu_compass/index_en.htm

Last updated: 28 June 2017Legal notice